Skip to main content
SpringerLink
Log in

Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Monoclonal antibody (MoAb) BrE-3, an anti-human milk fat globule (HMFG) MoAb, is used here as a novel prognostic indicator for survival and relapse time in patients with infiltrating ductal carcinoma of the breast. A scoring system (4-Score method) was developed to this effect that measured, in a statistically reliable fashion, the level of expression of the epitope for MoAb BrE-3 in the cytoplasm and membranes of breast carcinoma cells in paraffin-embedded sections. In univariate analysis, data obtained by the 4-Score Method as well as data from traditional prognostic indicators (tumor size, axillary node status, and grade of differentiation) were found to be associated with patient survival and relapse. In multivariate analysis, using a Cox proportional hazards regression model, levels of expression of BrE-3 epitope plus tumor size and axillary node status were weighted and combined in an Individual Linear Composite Prognostic Score (ILCPS) that had a high level of association with survival and relapse time in this sample model of patients with infiltrating ductal carcinoma of the breast. This level of association was found to be higher than the level of association for any other combination of traditional or 4-Score method variables. The level of expression of BrE-3 significantly adds to the prognostic capacity of traditional prognostic markers for infiltrating ductal carcinoma of the breast.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary node negative breast cancer patients. J Natl Cancer Inst 82:1006–1015, 1990.

    Google Scholar 

  2. Hyde-Hanley JM, Lynch RG: The physiology of B cells as studied with tumor models. Ann Rev Immunol 4:621–650, 1986.

    Google Scholar 

  3. Ellis IO, Hinton CP, MacNay J, Elston CW, Robins A, Owainati AARS, Blamey RW, Baldwin RW, Ferry B: Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J 290:881–883, 1984.

    Google Scholar 

  4. Wilkinson MJS, Howell A, Harris M, Taylor-Papadimitriou J, Swindell R, Sellwood RA: The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer 33:299–304, 1984.

    Google Scholar 

  5. Berry N, Jones DB, Smallwood J, Taylor I, Kirkham N, Taylor-Papadimitriou J: The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer 51:179–186, 1985.

    Google Scholar 

  6. Ceriani RL, Peterson JA, Lee JY, Monacada R, Blank EW: Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule. Somatic Cell Genet 9:415–427, 1983.

    Google Scholar 

  7. Peterson JA, Larocca D, Walkup G, Amiya R, Ceriani RL: Molecular analysis of epitope heterogeneity of the breast mucin.In: Ceriani RL (ed) Breast Epithelial Antigens: Molecular Biology to Clinical Applications. Plenum, New York, 1991, pp 55–68.

    Google Scholar 

  8. Hull SR, Bright A, Carraway KL, Abe M, Hayes DF, Kufe DW: Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun 1:261–267, 1989.

    Google Scholar 

  9. Ceriani RL, Rosenbaum E: Breast epithelial antigens in the circulation of breast cancer patients.In: Herberman RB, Mercer DW (eds) Immunodiagnosis of Cancer. Marcel Dekker Inc, 1991, pp 223–241.

  10. Ligtenberg MJL, Voss HL, Gennisen AMC, Hilkens J: A carcinoma associated mucin is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 265: 5573–5578, 1990.

    Google Scholar 

  11. Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky J, Kotkes P, Weiss M, Lathe R, Dion A, Keydar I: Human epithelial tumor antigen cDNA sequences. Eur J Biochem 189:463–473, 1990.

    Google Scholar 

  12. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265:15286–15293, 1990.

    Google Scholar 

  13. Peterson JA, Zava DT, Duwe AK, Blank EW, Battifora H, Ceriani RL: Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule. Hybridoma 9:221–235, 1990.

    Google Scholar 

  14. Ceriani RL, Peterson JA, Lamport D, Amiya R: Epitope expression on the breast epithelial mucin. Breast Cancer Res Treat 24:103–113, 1992.

    Google Scholar 

  15. Chevallier B, Mosseri V, Dauce JP, Bastit P, Julien JP, Asselain B: A prognostic score in histological node-negative breast cancer. Br J Cancer 61:436–440, 1990.

    Google Scholar 

  16. Shek LM, Godolphin W: Model for breast cancer survival: Relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 48:5565–5569, 1988.

    Google Scholar 

  17. Ashton Tate Corp: DBase IV. Ashton Tate Corp, Torrance CA, 1988.

    Google Scholar 

  18. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Brit J Cancer 11: 359–366, 1957.

    Google Scholar 

  19. Contesso G, Saccani Jotti G, Bonadonna G: Tumor grade as a prognostic factor in primary breast cancer. Eur J Cancer Clin Oncol 25:403–409, 1989.

    Google Scholar 

  20. Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, Schinella RA, Schwartz IS, Wheeler JE: Interobserver reproducibility of histopathological features in stage II breast cancer. Breast Cancer Res Treat 5:3–10, 1985.

    Google Scholar 

  21. Le Doussal V, Tubiani-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M: Prognostic value of histological grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64:1914–1921, 1989.

    Google Scholar 

  22. Fisher ER: Comment on “Interobserver reproducibility of histopathological features in stage II breast cancer.”, by KW Gilchrist, et. al. Breast Cancer Res Treat 5:11–13, 1985.

    Google Scholar 

  23. D'Amato MR: Experimental Psychology — Methodology Psychoanalysis and Learning. McGraw-Hill, 1970.

  24. Cohen J: A coefficient of agreement for nominal scales. Educational and Psychological Measurement 20:37–46, 1960.

    Google Scholar 

  25. Light RJ: Measures of response agreement for qualitative data: Some generalizations and alternatives. Psychological Bulletin 76:365–377, 1971.

    Google Scholar 

  26. Microsoft Corp: Microsoft Excel, Version 2.0. Microsoft Corp., Redmon WA, 1987.

    Google Scholar 

  27. SAS Institute Inc: Base SAS, Version 6.0. SAS Institute Inc., Cary NC, 1988.

    Google Scholar 

  28. SAS Institute Inc: The Lifetest Procedure. SAS Technical Report: P-179, Additional SAS/STAT Procedures, Release 6.03. SAS Institute Inc., Cary NC, 1988, pp 49–89.

    Google Scholar 

  29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457–481, 1958.

    Google Scholar 

  30. Greenwood M: The natural duration of cancer.In: Reports on public health of medical subjects, Vol 33. Her Majesty's Stationery Office, London, 1926, pp 1–26.

    Google Scholar 

  31. Kalbfleish JD, Prentice RL: The Statistical Analysis of Failure Time Data. John Wiley and Sons, New York NY, 1980.

    Google Scholar 

  32. Statistics and Epidemiology Research Corporation: Egret. Statistics and Epidemiology Research Corporation, Seattle WA, 1990.

  33. Cox DR, Oakes D: Analysis of survival data: Monographs on statistics and applied probability. Chapman and Hall, New York NY, 1988.

    Google Scholar 

  34. Rosen PP, Saigo PE, Brown DW: Prognosis in stage II(T1N1M0) breast cancer. Ann Surg 194:576–584, 1981.

    Google Scholar 

  35. Kister SJ, Sommers SC, Haagensen CD: Nuclear grade and sinus histiocytosis in cancer of the breast. Cancer 23:570–575, 1969.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. John Muir Cancer and Aging Research Institute, 94596, Walnut Creek, CA, USA

    Curtis M. Chan, Frank S. Baratta & Roberto L. Ceriani

  2. Department of Pathology, Columbia-Presbyterian Medical Center, 10032, New York, NY, USA

    Luciano Ozzello

Authors
  1. Curtis M. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank S. Baratta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luciano Ozzello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto L. Ceriani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, C.M., Baratta, F.S., Ozzello, L. et al. Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast. Breast Cancer Res Tr 30, 243–261 (1994). https://doi.org/10.1007/BF00665966

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00665966

Key words

Search

Navigation